Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

Martin Beaulieu's Biography

Martin Beaulieu, Director, Regulus Therapeutics Inc

Dr. Martin Beaulieu is a biochemist with expertise in the development of molecular applications and diagnostic assay development. In the past 16 years, Dr. Beaulieu has led research & development activities in academic and bio-pharmaceutical organizations. He holds a Bachelor of Science degree in Biochemistry (1993) from Laval University and a Ph.D. in Physiology-Endocrinology from the Faculty of Medicine (1998) at Laval University.
Dr. Beaulieu’s Ph.D. thesis focused on steroid hormones and drug metabolizing enzymes, called UGTs. His work contributed to the demonstration of the role of the UGT enzymes in controlling steroid hormones homeostasis and cellular hormonal response in cancer cells. He authored 20 peer-reviewed scientific publications. During a post-doctoral fellowship, Dr. Beaulieu developed a novel mutation detection assay at the Beckman Research Institute at the City of Hope National Medical Center in Duarte, CA. At Sequenom Inc., a genetic systems company in San Diego, he led the development and optimization of molecular applications based on MALDI-TOF Mass Spectrometry including the iPLEXTM genotyping product. At DiagnoCure Inc. Dr. Beaulieu led cancer biomarker discovery studies and the development of a high-value molecular diagnostic test for staging colorectal cancer (Previstage™). Recently, Dr. Beaulieu supported the management of diagnostic assay development at Abbott Point of Care and is currently leading the Regulus microMarkers™ R&D division at Regulus Therapeutics Inc.

Martin Beaulieu Image

MicroRNAs as Non-Invasive Biomarkers

Monday, 27 October 2014 at 16:15

Add to Calendar ▼2014-10-27 16:15:002014-10-27 17:15:00Europe/LondonMicroRNAs as Non-Invasive

Recent studies show that miRNAs are released from tissues into the circulation and the levels of specific miRNAs can be used as surrogates for the disease tissues. miRNAs are highly stable in the circulation due to the fact that they are protein bound and/or encapsulated in vesicles. We have developed and optimized a high-throughput platform that consistently measures over a hundred miRNAs from less than 200 microliters of serum, plasma and whole blood.  We also developed robust methods enabling miRNA profiling from other biofluid types such cerebrospinal fluid and urine.  Using this optimized platform, we conducted large-scale profiling studies to identify miRNA biomarkers in a wide variety of disease conditions.  We found distinct microRNA signatures distinguishing patients with multiple sclerosis from normal volunteers, patients with high risk of metastasis of colorectal cancer and other malignant diseases. We are also developing a microRNA signature that may be both prognostic and predictive for patients with rheumatoid arthritis.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid